Vect-Horus, a biotechnology company based in Marseille, France, is set to participate at the Viva Technology conference in Paris from May 22-25, 2024. The company specializes in designing molecular vectors that aid in the targeted delivery of therapeutic molecules and imaging agents.
France’s National Center for Scientific Research (CNRS) has selected 10 start-ups with innovative technologies to showcase at the event. Vect-Horus has been chosen to present their VECTrans® technology, which is a unique breakthrough in drug targeting for the brain and other pathological tissues such as cancers.
Jean-Manuel Pean, the Chief Scientific Officer of Vect-Horus, will be part of a roundtable discussion where he will provide an overview of the Company and its pipeline. He will discuss the progress made with the VECTrans® technology, the early clinical trials of their theragnostic agent for glioblastoma and pancreatic cancer, and provide updates on their partnerships, including agreements with Novo Nordisk and Ionis Pharmaceuticals.
Vect-Horus was founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University). They focus on developing vectors for targeting and delivering therapeutic or imaging agents to organs and tumors. With 38 employees, predominantly in research and development, Vect-Horus continues to make strides in the biotechnology field.
For more information about Vect-Horus, visit their website at www.vect-horus.com. For media inquiries or press releases